<?xml version="1.0" encoding="UTF-8"?>
<p>Reported adverse event rates in VMMC trial studies are 3.8% in SA, 3.6% in Uganda and 1.5% in Kenya.[
 <xref rid="pone.0190795.ref016" ref-type="bibr">16</xref>] These adverse event rates are favorable compared to adverse event rates in traditional circumcisions, which are as high as 35.2%.[
 <xref rid="pone.0190795.ref017" ref-type="bibr">17</xref>] While the adverse event rates associated with VMMC in developing countries are low compared to traditional circumcisions, they are higher than the VMMC adverse event rates reported in developed countries (0.2% to 0.6%). Adverse events are prevented by pre-screening clients and using a sterile surgical technique. [
 <xref rid="pone.0190795.ref018" ref-type="bibr">18</xref>] Classification and treatment for adverse events associated with VMMC are outlined in an Adverse Event Action Guide. [
 <xref rid="pone.0190795.ref019" ref-type="bibr">19</xref>]. Excessive bleeding (intra- and post-operative), infection, wound disruption and pain (intra- and post-operative) are common adverse events. [
 <xref rid="pone.0190795.ref019" ref-type="bibr">19</xref>]
</p>
